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Abstract—The highly selective I1-PBS imidazoline analogue PMS 952 has been selected to study the incidence of intramolecular
hydrogen bond and molecular ilexibility on its biological activity. On one hand, the weak energy dierence between three calculated
conformers does not support the stabilization of one conformer by an internal hydrogen bond. The 3-D electrostatic map confirms
this feature and the solvent eect does not significantly modify the relative energy of these conformers. On the other hand, the
conformational spaces of the neutral and ionized forms present a great number of equilibrium structures, in a short energetic range
(20 Kcal). The results are representative of an exceptional conformational flexibility due to a cooperative eect between several
parts of the molecule. # 2000 Elsevier Science Ltd. All rights reserved.
Introduction
In the past it has been established that many adrenergic
agents can also interact with discrete imidazoline recep-
tors I1 and I2 (for reviews, see Ref 1), named Imidazoline
Preferring Binding Sites (I-PBS). The discussion is open
about the nature of the I-PBSs. It was proved that adre-
noreceptors and I1ÿ2-PBSs are biochemically dierent2,3
and that the structure of isolated I2-PBS depends on the
animal origin, organs and cells.4,5 Moreover I1 and I2-PBS
may interconnect in human striatum.6 In the present
publication, we examine the binding anity and the
selectivity of a new imidazoline analogue trans-1-(40,50-
dihydro-10H-imidazol-20-yl)methyl-2-hydroxyindane 5
(PMS 952) (see Scheme 1 and Fig. 1). This compound
was selected into a large series of imidazoline derivatives
which will be published later. Its intra and intermolecular
H-bonds could influence the molecular flexibility and its
interactions with the receptor(s).
In the present work, we analyze the geometry flexibility of
PMS 952 depending on both main rotators defining the
relative position of the imidazoline and the indane rings for
the ionized and neutral forms. In fact, several cooperative
conformational eects could also occur involving the imi-
dazoline N-H inversion, the alcohol rotation and the rela-
tive distortion of the cyclopentane fragment. The OH and
NH functions could also be involved in intermolecular H-
bonds which will be modelized by a dimer of PMS 952.
The question of ionization of the imidazoline ring in the
physiological medium was examined in our previous
publications.7 The short range of pKa values around 8
units whatever the molecular skeleton of the analogue
(here with an additional spacer that eliminates all elec-
tronic influences) nullifies a priori the influence of this
factor as a determinative parameter on the variations of
the biological activity in an homogeneous series. Two
other factors can be taken into account: (i) the local pH
inside the site of interaction is unknown and assumed to
be constant and (ii) if the imidazoline nitrogen is proto-
nated, the positive charge is probably counterbalanced
by electrostatic interaction with the carboxylate of an
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aspartate or glutamate moiety in the receptor site. Never-
theless, all energetic data have been calculated in both
neutral and ionized forms.
Chemistry
The enamine 1 (see Scheme 1) was prepared by the con-
densation of pyrrolidine with indan-2-one. Alkylation of
the enamine with ethyl bromoacetate led to the g-ceto
ester 2 after hydrolysis.8 Reduction of 2 with sodium
borohydride at ÿ5 C in ethanol9 provided a mixture of
trans alcohol 3 and lactone 30, which resulted from a cycli-
sation of the cis alcohol. The hydroxyl groupwas protected
with trimethylsilyle before introducing the imidazoline
group.10 The deprotection has been occured during the
treatment of the reaction from ester to imidazoline.7
Results and Discussion
Biological results
PMS 952 has a high anity for the I1-PBS (22 nM) and a
high binding selectivity versus adrenoreceptors (ratio/a2:
145.5 and /a1: 250). PMS 952 presents a moderate anity
on the I2-PBS (5.4 times less) and lower selectivities con-
cerning adrenoreceptors (Table 1).
Conformational analysis of the free base
The molecule presents three rotatable bonds involved in
the conformation of the alcohol and the imidazoline
group. Their mutual incidence could generate at least
three types of conformers: (i) without any intramole-
cular H-bond I, (ii) with one H-bond between the O-H
group and the imidazoline N sp2 II, and (iii) between the
O-H and the imidazoline H-N sp3 III (Fig. 1). These con-
formers have been located by full geometry optimization
at the ab initio level involving the MINI-10 minimal basis
Scheme 1. Reagents. (a) pyrrolidine, benzene, reflux; (b) i. BrCH2CO2Et, EtOH, 18 h; ii. H2O; (c) NaBH4, EtOH,ÿ5 C; (d) Me3SiCl, Et3N, THF, 0 C;
(e) i. DAE,Me3Al, toluene, 80
C; ii. HCl/MeOH.
Figure 1. Conformers of PMS 952 without (I) and with intramolecular H-bond (II and III).
Table 1. Binding assays and selectivity of PMS 952 on adreno-
receptors and IPBsa
Ki (nM) Selectivity









145.5 250 26.6 45.8 5.4
aBinding assays: see Experimental.
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set,11 the double z 6-31G without12 and with additional
polarization functions 6-31G*.13
Totally in accordance with the X-ray structure of the
free base,14 the conformer II, the most stable one, pre-
sents an intramolecular H-bond of 1.92, 1.94, and 1.99 A˚
in the three basis sets. In the conformation III, with the
other H-bond type, the distance remains in the same
range: 1.85, 2.01, and 2.08 A˚.
Nevertheless, the energy dierence between the three
conformers does not significantly support a high stabi-
lization of one of them by an internal H-bond. Indeed,
conformers I, without H-bond, and III, with the other
type of H-bond, are only approximatively 4.5Kcal less
stable than conformer II (Table 2). These results are
also confirmed by the higher level calculation B3Lyp
either at the optimized 6-31G or 6-31G* geometries.
In the conformation II, the 3-D electrostatic potential
map clearly shows that both nitrogens are surrounded
by a negative envelope at ÿ20Kcal/mol with the same
shape (Fig. 2), the absolute minimum (ÿ74.3Kcal/mol)
lying near the oxygen. As previously discussed,15 a
negative envelop also appears over the aromatic part of
the indane.
Solvent eects
For the three main representative conformers, the inci-
dence of the solvent has been investigated by a complete
reoptimization at the 6-31G level using the Onsager’s
model.16 For CCl4, CHCl3 and acetonitrile, the dielec-
tric constant e is 2.2, 4.8, and 38, respectively. The
energetic results (Table 3) are not significantly modified
for the conformer III as the dierence between con-
formers II and III remains in the range of 5.475 (e=1)
to 5.876 (e=38)Kcal/mol as if the intramolecular H-
bond was not influenced by the solvent. This dierence
is slightly increased for conformer I going from 6.241
(e=1) to 7.307 (e=38)Kcal/mol.
These first results suggest that PMS 952 could interact
with Imidazoline Binding Sites via expected inter-
molecular H-bonds. Such interactions could be related
with the exceptional flexibility of this molecule, in spite of
the putative intramolecular H-bond which is rather weak.
Remarkably this molecule can adopt several conforma-
tions significantly dierent in their geometry, but lying
in a very small energetic range. It is the reason why a
more extensive investigation of the conformational
adaptibility has to be performed.
2-D Conformational analysis
A complete scan of the conformational space has been
performed using the conformer II as starting point. A two
dimensional map has been calculated following both
dihedral angles of the methylene group linking the imida-
zoline to the cyclic part of the molecule. At each step of
the 15 degrees regular mesh for these two degrees of free-
dom (dof), all the other 3N-8 ones have been re-optimized
at the MINI-10 ab initio level.17
The 2-D isoenergetic contour map (Fig. 3) highlights the
complex ways that the molecular system could follow to
go from one conformer to another within a maximum
15Kcal range. Depending on the considered edges of
the surface quite as much as 21 equilibrium structures
have been located on this map (Table 4). In a second
step, these conformers: 13 minima, 5 transition state
structures and 3 second order critical points have been
fully optimized and characterized by analytical frequency











Conformers E G E G E G E E
I 5.760 4.393 6.241 5.514 4.244 3.935 5.610 5.040
II 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
III 3.240 3.340 5.475 5.274 4.562 4.140 5.012 4.698
aAll the values are expressed in Kcal/mol. G is calculated at 298.15  K and at 1 atmosphere.
Table 3. Solvent eect on relative energy values
6-31G//6-31G
Conformers E (Kcal/mol) G (Kcal/mol)
CCl4 CHCl3 CH3CN CCl4 CHCl3 CH3CN
I 6.723 7.030 7.307 5.851 6.209 6.645
II 0.000 0.000 0.000 0.000 0.000 0.000
III 5.675 5.788 5.876 5.398 5.462 5.504
Figure 2. Ab initio MINI-10 3-D electrostatic potential isocountoured
at ÿ20Kcal/mol for the MINI-10 optimized conformation II.
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calculation. With regard to the conformer II, the less
stable in energy structure is the second order point XIX.
Remarkably, three other minima (IV, VI and XVI)
more stable than conformer I have also been localized.
They confirm the very high geometric flexibility of this
molecule due to a combination of eects as the rotation of
the alcohol and the inversion of the NH imidazoline
nitrogen. The two second order critical points (P.C. 2) are
characterized by two negative hessian eigenvalues corre-
sponding to energy maxima for the two dihedral angles
and all the other positive ones to energy minima in all
Figure 3. (a) Neutral molecule: energetic isocontours from 2Kcal (red) to 15Kcal (blue) including isocontour 7.5Kcal (green). Horizontal axis: p2;
vertical axis: p1. (b) Perspective view of the 2-D conformational map showing the valleys joining one conformer to another. Going up axis: p1 going
down axis: p2.
Figure 4. Selection of six equilibrium structures of the neutral form. The TS XV structure connects the minima II and IV. The interatomic H-bond
distances are expressed in A˚.
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the other directions. It can be noted that, on the same
surface, two P.C. 2 have a E lower than the first order
critical point TS XI. The incidence of the entropy term
significantly varies on the free energy value depending
on the nature of the critical point. In fact, this term is
lower for the first and second order points when com-
pared to the minima. Six equilibrium structures are
drawn on the Figure 4. As illustrated on the map (Fig.
3), the TS XV connects the minima II and IV mainly via
the maximum energy path following the dihedral angle
p2. Having the same type of intramolecular H-bond,
minima III and VI dier from one another in their p2
value and mainly in the sp3 nitrogen inversion while
they remain in the same energetic range of 3.5Kcal/mol
in G.
The O-H position in the conformer III on one hand and
the observed crystal packing on the other hand suggest
that an intermolecular H-bond could also appear
between the oxygen of the alcohol of one molecule and
the N-H of the neighbouring one.14
Intermolecular model
As a model of intermolecular interaction capability of this
compound, a dimer has been fully optimized using MINI-
10 and the two extended basis sets 6-31G and 6-31G*.
Depending on the basis set size, the intramolecular H-
bond is slighly shorter in the dimer than in the isolated
form. The intermolecular H-bond is of the same order
between 1.745 A˚ (MINI-10) and 2.104 A˚ (6-31G*). The
MINI-10 conformer looks like the X-ray conformation
whereas the optimized structures in double z are sig-
nificantly twisted (Fig. 5). The energetic results are given
in Table 5. With 544 basis functions, the analytical fre-
quency calculation could not be run for the 6-31G*
dimer. Two results are remarkable: the entropy factor of
the dimer is significantly smaller than twice the entropy
term of each monomer thus leading to a nonstabilizing
G at 298.15 K and 1 atm. The second point concerns
the very weak deformation energy by comparison
between the interaction and complexation energy. At
their geometry in the dimer, each monomer does exhibit
only a small energy dierence by reference to the iso-
lated optimized geometry as given by the complexation
energy.
Conformational analysis of imidazoline protonated
compound
A priori, the local symmetry of the protonated imida-
zoline reduces the number of equilibrium structures
which can be located in the 2-D conformational map
(Fig. 6). It has been computed following the same pro-
cedure that was applied for the neutral molecule. Nine
conformers have been characterized as critical points at
Figure 5. MINI-10 optimized conformation of the dimer. The inter-
atomic H-bond distances are expressed in A˚.
Table 4. Dihedral angles and energy values of 21 equilibrium struc-
tures of the neutral forma
Dihedral anglesb
Conformation p1 p2 Entropy E G
I min 64.55 100.38 118.430 5.760 4.394
II min 181.95 ÿ9.21 115.132 0.000 0.000
III min ÿ165.31 129.40 114.780 3.240 3.340
IV min ÿ174.90 106.51 114.013 3.005 3.423
V TS ÿ159.51 153.38 112.302 7.236 7.314
VI min 176.32 ÿ158.98 116.201 3.910 3.494
VII TS ÿ117.21 131.58 111.689 7.542 7.592
VIII P.C. 2 ÿ122.51 175.75 107.463 11.489 12.184
IX TS ÿ88.31 53.51 112.130 8.848 8.694
X min ÿ82.71 114.93 117.749 6.027 4.836
XI TS ÿ2.72 ÿ99.75 112.881 12.348 12.006
XII min 43.20 ÿ150.72 117.889 7.968 6.802
XIII min 56.64 23.75 120.481 7.321 5.336
XIV min 56.54 ÿ100.85 118.214 8.761 7.457
XV TS 179.20 82.09 119.453 7.758 5.272
XVI min 181.42 ÿ115.59 120.553 5.529 3.523
XVII P.C.2 ÿ129.02 77.59 108.890 11.207 11.323
XVIII min ÿ85.61 ÿ14.00 119.359 7.186 5.404
XIX PC 2 128.33 190.02 108.379 21.224 21.724
XX min ÿ179.30 ÿ104.44 119.529 5.932 4.185
XXI min 67.51 111.92 118.876 6.839 5.249
aMin: zero order critical point, true minimum; TS: first order critical
point, transition state structure; P.C. 2: second order critical point:
energy maximum in both directions p1, p2.
bEntropy in cal/mol. E and G in Kcal/mol. Dihedral angles in
degrees. p1: C2
0-C10-C1-C8, p2: N3-C20-C10-C1, after re-optimization
of all the 3N-6 degrees of freedom.
Table 5. Energy values of the dimera
Entropy (calories) Complexation Energy Interaction Energy
2Monomer//Monomer Dimer//Dimer E (Kcal/mol) G (Kcal/mol) E (Kcal/mol)
MINI-10 230.264 201.764 8.523 ÿ2.338 9.306
6-31G 227.802 194.608 10.161 ÿ2.151 10.783
6-31G* — — 7.612 — 7.998
aSee text and experimental.
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the MINI-10 level (Table 6). The energy range connect-
ing all these structures is rather similar at the results
derived from the neutral analysis except that the energy
dierence between the minima is more significant. The
most striking feature is given by the comparison
between the two more stable conformers in the neutral
(II) and protonated molecule (I) (Fig. 7). The relative
position of the imidazoline ring is quite similar, the
main dierence between these conformers being the
alcohol rotation.
Conclusion
The molecular flexibility of PMS 952 has been investi-
gated by a 2-D regular 15 degrees conformational map
in which all the 3N-8 degrees of freedom of the 625
points were fully optimized at the MINI-10 ab initio
level. No more stable conformer than the previously
described one II has been found but new stable minima
and their related transition state structures have been
located. Remarkably, one second order critical point,
with a maximum energy following the two investigated
dihedral angles, lies in energy lower than a first order
critical point. It can be concluded that PMS 952 pre-
sents a significant conformational flexibility which could
have a great incidence on its anity towards the I-PBS
Figure 7. Most stable conformers in the neutral (II) and in the proto-
nated (I)molecules. The interatomicH-bonddistances are expressed in A˚.
Figure 6. (a) Protonated molecule: energetic isocontours from 2Kcal (red) to 15Kcal (blue) including isocontour 7Kcal (green). Horizontal axis: p2;
vertical axis: p1. (b) Perspective view of the 2-D conformational map showing the valleys joining one conformer to another. Going up axis: p1; going
down axis: p2.
Table 6. Dihedral angles and energy values of nine structures calcu-
lated at the equilibrium for the protonated forma
Dihedral anglesb
Conformation p1 p2 Entropy E G
I min ÿ174.06 ÿ22.39 113.350 0.000 0.000
II TS ÿ172.05 ÿ88.55 113.381 11.950 11.322
III min 61.81 48.77 117.604 12.188 10.851
IV min ÿ80.68 ÿ57.69 119.503 13.387 11.486
V min ÿ65.45 ÿ84.34 120.358 14.458 12.237
VI TS ÿ121.27 ÿ125.38 114.488 15.039 14.075
VII min 60.96 146.43 114.376 15.737 14.522
VIII P.C. 2 ÿ14.89 ÿ38.97 106.828 21.090 21.684
IX min 123.54 ÿ90.73 113.317 22.490 21.709
aFor definitions, see Table 4.
bAfter re-optimization of all the 3N-6 dof.
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receptors. Moreover the conformational similarities
between the most stable conformer in neutral and pro-
tonated forms has to be pointed out. As the hydroxyl
group rotation is relatively free, an intermolecular H-
bond with the receptor may be expected in both forms,
but at least, many other factors would determine selec-
tivity between I-PBS and adrenoceptors binding.
Experimental
Calculations
All the calculations were performed with gaussian 9417
on two computers, a Dec Alpha 8400 8 processor and a
Dec Alpha 4100 4 processor. For all the systems, a full
geometry optimization was done at the Hartree-Fock
level with the minimal MINI-10 basis set.11 The nature of
the critical points was determined by the frequency ana-
lytical calculation. The free energies were computed from
the analytical frequencies through the usual statistical
mechanics formulas at 298.15 K and 1 atmosphere.18
Chemistry
The purity of each compound was checked by thin-layer
chromatography on TLC plastic sheets (silica gel 60F254,
layer thickness 0.2mm) from Merck. Column chromato-
graphy purification was carried out on silica gel 60 (par-
ticle size 0.063–0.200mm) from Merck, without any
special treatment. All melting points were determined in a
digital melting point apparatus (Electrothermal) and are
uncorrected. The structures of all compounds were con-
firmed by IR and 1H NMR spectra. IR spectra were
obtained with a ATI Mattson Genesis Series FTIR infra-
red spectrometer, and 1H NMR spectra were recorded in
CDCl3 on a BRUCKER AC 200 spectrometer using
hexamethyldisiloxane (HMDS) as an internal standard.
Pyrrolidine enamine of 2-indanone (1). A solution of 2-
indanone (30 g, 0.23mol) and pyrrolidine (24 g, 0.35mol)
in 200mL of benzene was refluxed for 3 h under nitrogen
using a Dean–Stark apparatus to eliminate water. After
removal of the solvents under reduced pressure, 42 g
(100%) of crude enamine (1) were obtained: Rf 0.66
(ether:petroleum ether, 50:50, v/v).
Ethyl (indan-2-on-1-yl)-acetate (2). To a solution of
enamine (1) (39 g, 0.21mol) in 200mL of dry methanol
was added dropwise ethyl bromoacetate (36.3 g, 0.21mol).
The solution was refluxed for 18h, and after addition of
9mL of water, refluxing was continued for another hour.
Addition of water (200mL) and extraction with ether
gave, after drying and distillation, 22.2 g (48.24%) of g-
keto ester (2) as a white oil: bp0.2mmHg 151–152
C;mp 47–
47.5 C; Rf 0.30 (ether:petroleum ether, 20:80, v/v): IR
(film) n 1750 (CO), 1735 (CO ester); 1H NMR d 7.25
(4H, m, ArH), 4.05 (2H, m, CO2CH2), 3.7 (1H, t, J=5.5
Hz, CH), 3.55 (2H, s, CH2CO), 2.95 (2H, d, J=5.5 Hz,
CH2CO2), 1.15 (3H, t, J=7.5Hz, CH3).
trans -1 - (Ethoxycarbonylmethyl) -2 -hydroxyindane (3).
NaBH4 (3.8 g, 0.1mol) was added in portions to a stirred
solution of keto ester (2) (21.8 g, 0.1mol) in 150mL of
95% EtOH at ÿ5 C. After the addition was complete,
the reaction was maintained in the same conditions
(ÿ5 C) with stirring for 3 h. Then it was quenched with
water (200mL) and the mixture was extracted with
ether three times. The extracts were combined, washed
with H2O and brine, dried (MgSO4), and evaporated.
Purification of the residue by column chromatography
on silica gel using ether:petroleum ether (10:90, v/v) as
eluent gave 14.3 g (65%) of the alcohol (3): Rf 0.15 (ether:
petroleum ether, 50:50, v/v); IR (film) n 3440 (O-H), 1731
(CO); 1H NMR d 7.12 (4H, m, ArH), 4.31 (1H, ddd,
J=9.7, 7.4 and 2.5Hz, CH-O), 4.15 (2H, q, J=2.5Hz,
CO2CH2), 3.79 (1H, d, J=2.5Hz, D2O exchangeable,
OH), 3.33 (1H, ddd, J=11.5, 7.2 and 6.3Hz, CH-Ph), 3.21
(1H, dd, J=15.9 and 7.3Hz, one H of CH2-Ph), 2.94 (1H,
dd, J=16.8 and 4.4Hz, one H of CH2CO2), 2.87 (1H,
J=15.8 and 7.4Hz, one H of CH2-Ph), 2.46 (1H, dd,
J=16.8 and 10.3Hz, one H of CH2CO2), 1.24 (3H, t,
J=7.1Hz, CH3).
trans -1-(Ethoxycarbonylmethyl)-2-(trimethylsilyloxy)-
indane (4). To a stirred solution of the alcohol (3) (14 g,
64mmol) and 20mL of Et3N in 100mL of THF at 0
C
was added dropwise chlorotrimethylsilane (10.4 g,
96mmol). After the addition, the stirring was continued
at room temperature for 8 h. The mixture was evapo-
rated in vacuo and the residue was dissolved in water
(30mL) and extracted three times with ether. The com-
bined ether extracts were dried (MgSO4) and evapo-
rated under vacuum to yield 18.1 g (96.8%) of (4) as a
white oil: Rf 0.59 (ether:petroleum ether, 50:50, v/v); IR
(film) n 1737 (CO); 1H NMR d 7.09 (4H, m, ArH),
4.18 (1H, dd, J=13.4 and 6.7Hz, CH-OSi), 4.11 (2H, q,
J=7.1Hz, CO2CH2), 3.40 (1H, dd, J=13.6 and 6.7Hz,
CH-Ph), 3.05 (1H, dd, J=15.4 and 6.7Hz, one H of CH2-
Ph), 2.76 (1H, dd, J=15.4 and 6.9Hz, one H of CH2-Ph),
2.56 (1H, d, J=2.0, one H of CH2CO2), 2.52 (1H, d,
J=2.7Hz, one H of CH2CO2), 1.21 (3H, t, J=7.4Hz,
CH2CH3), 0.90 (9H, s, Si(CH3)3).
trans-1-(40,50-Dihydro-10H-imidazol-20-ylmethyl)-2-hydro-
xyindane (5). Trimethylaluminium (90mL of a 2M
solution in toluene, 0.18mol) was added dropwise to a
stirred solution of ester (4) (17.5 g, 0.06mol) in 120mL
of toluene at 0 C, followed by ethylenediamine (8mL,
0.12mol). After the addition, the reaction mixture was
heated at 80 C for 6 h, then cooled with an ice bath and
treated dropwise with water (30mL). After decantation,
the aqueous layer was extracted two times with toluene.
The organic phases were combined, washed with H2O
and brine, dried over MgSO4, and filtered. The solvent
was evaporated in vacuo and the residue, taken up in
100mL of HCl saturated methanol, evaporated again
under vacuum, was crystallized in CH3OH:CH2Cl2:
ether (5:80:20, v/v/v) giving 13.5 g (88.8%) of (5, HCl),
as white crystals: mp 176–177 C; Rf 0.21 (CH3OH:
CHCl3, 10:90, v/v) on Al2O3. IR (paran) n 3250 (OH),
3198 (NH); 1H NMR d 7.11 (4H, m, ArH), 5.90 (2H,
br s, D2O exchangeable, NH and OH), 4.26 (1H, dd,
J=16.8 and 7.8Hz, CH-O), 3.58 (4H, s, two N-CH2),
3.29 (1H, m, CH-Ph), 3.21 (1H, dd, J=15.7 and 7.7Hz,
one H of CH2-Ph), 2.95 (1H, dd, J=17.0 and 2.9Hz, one
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H of CH2-CN), 2.89 (1H, dd, J=16.8 and 9.8Hz, one
H of CH2-Ph), 2.26 (1H, dd, J=16.9 and 11.7Hz, one H
of CH2-C). Anal. calcd for C13H16N2O.HCl: C, 61.78;
H, 6.78; N, 11.08. Found: C, 61.46; H, 6.60; N, 10.87.
Pharmacology
General procedure. Tissue and membrane preparation.
Cerebral cortex was obtained from whole bovine brains
and homogenized in 20 volumes of ice-cold 50mM Tris–
HCl buer (pH 7.4). The homogenate was centrifuged
twice at 48 000 g for 25min at 4 C. The pellet (used for
a2-binding assays) was resuspended in a phosphate buf-
fer (pH 7.4), flash-frozen and stored at ÿ80 C until a2-
binding assays.
Reticular nucleus from calf’s bulbis was homogenized in
ice-cold 50mM Tris–HCl buer (pH 7.7) containing
5mM EDTA. The homogenate was centrifuged at 500 g
for 10min at 4 C. The pellet (P1) was resuspended in the
same buer and centrifuged again. The combined super-
natants were centrifuged at 50 000 g for 25min at 4 C.The
resulting pellet (P2) was resuspended in 50mM Tris–HCl
buer (pH 7.7) containing 0.1mM paramethylsulfonyl-
fluoride and incubated for 30min at 25 C, then cen-
trifuged again in the same conditions and resuspended
in 50mM Tris–HCl (pH 7.7), flash-frozen and stored at
ÿ80 C until I1-binding assays.
Renal cortex was obtained frommale New Zealand white
rabbits and homogenized in ice-cold preparation buer
(20mM NaHCO3). The homogenate was centrifuged at
40 000 g for 30min at 4 C. The pellet was resuspended in
50mM Tris–HCl buer containing 0.5mM EDTA (pH
7.4), centrifuged again and resuspended in the same buf-
fer, flash-frozen and stored at ÿ80 C until I2-binding
assays.
Binding assays. [3H]RX 821002 (48Ci/mmol), [3H]cloni-
dine (50Ci/mmol), and [3H]idazoxan (42Ci/mmol) were
obtained from Amersham (Buckinghamshire, UK), and
phentolamine, guanabenz, tolazoline, idazoxan, yohim-
bine, clonidine, naphazoline and amiloride from Sigma (St
Louis, MO). Radioligand binding assays with [3H]prazo-
sine, [3H]RX 821002, [3H]clonidine, or [3H]Idazoxan for
determination of specific binding to a1 and a2-adreno-
ceptors and anity for I1 and I2-Preferring Binding
Sites, were respectively evaluated by a modification of
methods previously described (see Ref 7). Membranes
were slowly thawed and diluted to a concentration of
0.4mg protein/mL for renal and cerebral cortex and
0.7mg protein/mL for calf’s bulbis. Assays were con-
ducted in a total volume of 525mL in polypropylene
tubes, and each tube contained 500mL of membrane sus-
pension, 20mL of radioligand and 5mL of drug. Incuba-
tion was initiated by the addition of membrane and was
carried out for 45min at 25 C. Nonspecific binding was
defined in the presence of yohimbine (10 mM) in [3H]RX
821002 binding assays, either phentolamine (10 mM) or
guanabenz (5 mM) in [3H]clonidine binding assays and
either tolazoline (10 mM) and amiloride (10 mM) in
[3H]idazoxan binding assays. For each drug, 12 con-
centrations from 10ÿ4 to 10ÿ11M were used in triplicate.
Incubations were terminated by vacuum filtration over
Whatman GF/B glass fiberfilters using a cell harvester.
The filters were washed three times with the buer, placed
in scintillation vials, covered with 2mL of scintillation
cocktail (Pico-Fluor, Packard Instrument) and counted
(Packard 2000 CA). Protein concentration was eval-
uated by the Bradford method.
Binding results were analysed using the iterative non
linear least square fitting with graph pad software
(Institut for Scientific Information, Philadelphia, PA).
Results are expressed as KiSEM.
Ki were determined using Cheng-Pruso method.
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